Skip to main content
Clinical Trials/DRKS00029567
DRKS00029567
Completed
Not Applicable

A non-interventional, prospective, multicenter study to describe patient preference and real-world outcomes of Diroximel Fumarate for the treatment of relapsing remitting multiple sclerosis in daily clinical practice - VIKY-GER Study

Biogen GmbH0 sites118 target enrollmentJuly 21, 2022
ConditionsG35.1

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
G35.1
Sponsor
Biogen GmbH
Enrollment
118
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 21, 2022
End Date
December 31, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Established clinical diagnosis of relapsing\-remitting MS
  • 2\. Able to understand the purpose and risks of the study, ability and willingness to follow study procedures, and provide signed and dated study\-specific informed consent form (ICF)
  • 3\. Having been prescribed treatment with Vumerity (DRF) or Tecfidera (DMF) according to label and local market reimbursement criteria and treatment is planned to be initiated within 30 days after enrollment or already initiated, with enrollment occurring no more than 30 days after the first dose.
  • 4\. Patients aged 18 years or above

Exclusion Criteria

  • 1\. Contraindication to dimethyl or diroximel fumarate treatment according to SmPC
  • 2\. Unable or unwilling to provide informed consent
  • 3\. Progressive forms of MS
  • 4\. Have received the newly prescribed treatment with DRF / DMF for more than 30 days
  • 5\. Have been prescribed another DMF than Tecfidera

Outcomes

Primary Outcomes

Not specified

Similar Trials